Some other clinical research hotspots related to chemotherapy and immunotherapy of ESCC are characterized by highly developed but isolated with marginal importance for the field, such as cisplatin, docetaxel, and EGFR. This evidence concerns the gene EGFR and esophageal squamous cell carcinoma.